HitGen Inc. (SHA:688222)
China · Delayed Price · Currency is CNY 35.87
+2.42 (7.23%)
At close: Jul 10, 2026
HitGen Market Cap
HitGen has a market cap or net worth of 14.37 billion as of July 10, 2026. Its market cap has increased by 121.01% in one year.
Market Cap
14.37B
Enterprise Value
13.64B
Revenue
579.37M
Ranking
n/a
PE Ratio
119.34
Stock Price
35.87
Market Cap Chart
Since April 16, 2020, HitGen's market cap has decreased from 18.86B to 14.37B, a decrease of -23.81%. That is a compound annual growth rate of -4.27%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 10, 2026 | 14.37B | 53.44% |
| Dec 31, 2025 | 9.37B | 90.34% |
| Dec 31, 2024 | 4.92B | -17.81% |
| Dec 29, 2023 | 5.99B | 10.86% |
| Dec 30, 2022 | 5.40B | -42.61% |
| Dec 31, 2021 | 9.41B | -22.01% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Apr 16, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Chengdu Olymvax Biopharmaceuticals | 18.01B |
| Sinocelltech Group | 17.58B |
| Anhui Anke Biotechnology (Group) | 13.72B |
| Mabwell (Shanghai) Bioscience | 13.66B |
| BrightGene Bio-Medical Technology | 13.57B |
| Jinyu Bio-technology | 13.31B |
| InventisBio | 12.96B |
| Staidson (Beijing) BioPharmaceuticals | 11.57B |